然而CAR T疗法针对胶质母细胞瘤（Glioblastoma，GBM）在内的诸多实体瘤效果却十分有限。为了进一步提升CAR T细胞在治疗实体瘤时的疗效，当前大多数研究致力于改良CAR ...

Here, we have developed a method to insert LT-scFv into the membranes of prokaryotic and eukaryotic cells rapidly and efficiently (Fig. 1). Purified LT-scFvs are brought into contact with cells ...

具有全球独特的CD19 scFv（HI19a）结构和国际*的生产制造工艺。源瑞达®（纳基奥仑赛注射液）是*具有中国全自主知识产权CD19 CAR-T细胞治疗产品。

近日，纽迈生物科技（苏州）有限公司（简称“纽迈生物”）基于其新一代全人源抗体转基因小鼠模型——NeoMab，推出了全新的合作模式：提供活体小鼠（NeoMab-IgG Ease）给客户自行免疫，无里程碑费用，显著简化了抗体药物的研发流程，使商业合作变得更加高效便捷。

证券之星消息，2024年11月4日百普赛斯（301080）发布公告称公司于2024年10月30日接受机构调研，华夏基金、南方基金、长城基金、广发基金、东吴证券、兴业证券、招商证券、其他89家机构参与。 具体内容如下： 问：公司 2024 年三季度业绩 ...

Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet”) (NASDAQ: SONN), a clinical-stage company developing ...

FMC63, an IgG2a mouse monoclonal antibody, targets CD19. To date, a majority of the reported CART19 trials include the anti-CD19 scFv extracted from FMC63, such as both the FDA-approved CARs ...

The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic ...

CARGO Therapeutics (CRGX) announced that its first abstract on CRG-023 will be presented as a poster at the upcoming 66th American Society of ...

We therefore have been developing new ways to inhibit HIV infection. In a long-term collaboration, we have created a novel method of converting nonneutralizing anti-HIV-1 envelope single chain Fv ...